V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330003088 | 330001638 | 1.67 | 67.75 | Curative (C) | 2016-06-19 | 2016-06-19 | Carboplatin AUC 2 - 5 | 02 | N | 330012140 | CARBOPLATIN |
| 330003089 | 330001638 | 1.72 | 63.7 | Disease modification (D) | 2016-04-06 | 2016-04-12 | Bendamustine+Rituximab(Sub Courses) | 2 | N | 330012140 | BENDAMUSTINE + RITUXIMAB |
| 330003090 | 330001638 | 1.53 | 63.5 | Neo-adjuvant (N) | 2017-11-28 | 2017-11-28 | Cisplatin + Doxorubicin | N | N | 330012140 | CISPLATIN + DOXORUBICIN |
| 330003091 | 330001638 | 1.8 | 55 | Curative (C) | 2016-01-02 | 2016-01-09 | BENDAMUSTINE + RITUXIMAB | N | N | 330012140 | BENDAMUSTINE + RITUXIMAB |
| 330003092 | 330001638 | 1.75 | 87.4 | Palliative (P) | 2015-04-14 | 2015-04-14 | Liposomal Doxorubicin (Caelyx) | 02 | N | 330012140 | LIPOSOMAL DOXORUBICIN |
| 330003093 | 330001638 | 1.61 | 58 | Disease modification (D) | 2015-05-18 | 2015-05-31 | BENDAMUSTINE + RITUXIMAB | 02 | N | 330012140 | BENDAMUSTINE + RITUXIMAB |
| 330003094 | 330001638 | 1.88 | 116.4 | null | 2016-11-18 | 2016-12-10 | Cisplatin + Doxorubicin | 02 | N | 330012140 | CISPLATIN + DOXORUBICIN |
| 330003095 | 330001638 | 1.84 | 77 | Palliative (P) | 2013-02-19 | 2013-03-13 | CARBOPLATIN + ETOPOSIDE | N | N | 330012140 | CARBOPLATIN + ETOPOSIDE |
| 330003096 | 330001638 | 1.82 | 71 | Palliative (P) | 2016-02-22 | 2016-02-26 | CARBOPLATIN + ETOPOSIDE | N | N | 330012140 | CARBOPLATIN + ETOPOSIDE |
| 330003097 | 330001639 | 1.57 | 87.7 | null | 2017-05-18 | 2017-06-01 | Cisplatin + Doxorubicin | N | N | 330012171 | CISPLATIN + DOXORUBICIN |
| 330003098 | 330006871 | 1.58 | 48.2 | Curative (C) | 2017-12-15 | 2017-12-30 | Carboplatin + Etoposide iv&po | N | N | 330012172 | CARBOPLATIN + ETOPOSIDE |
| 330003099 | 330006871 | 1.73 | 66 | null | 2018-06-02 | 2018-06-19 | Doxorubicin 75mg/m2 | N | N | 330012172 | DOXORUBICIN |
| 330003100 | 330006871 | 1.77 | 76.2 | Disease modification (D) | 2014-03-25 | 2014-04-14 | Liposomal Doxorubicin (Caelyx) | N | N | 330012172 | LIPOSOMAL DOXORUBICIN |
| 330003101 | 330001640 | 1.71 | 61.5 | Neo-adjuvant (N) | 2014-08-01 | 2014-08-14 | CNS GCT II Germinoma - Carbo Etop | 02 | N | 330012178 | CARBOPLATIN + ETOPOSIDE |
| 330003102 | 330001640 | null | 102 | Palliative (P) | 2016-05-24 | 2016-06-28 | Doxorubicin 75mg/m2 | N | N | 330012178 | DOXORUBICIN |
| 330003103 | 330009708 | 1.71 | 78.5 | Palliative (P) | 2014-11-18 | 2014-11-26 | Rituximab | 02 | N | 330012185 | RITUXIMAB |
| 330003104 | 330001641 | 1.6 | 100.6 | Curative (C) | 2014-12-13 | 2014-12-14 | Cisplatin + Doxorubicin | 2 | N | 330012188 | CISPLATIN + DOXORUBICIN |
| 330003105 | 330001642 | 1.88 | 55.8 | Neo-adjuvant (N) | 2014-09-29 | 2014-09-29 | Cisplatin + Doxorubicin | N | N | 330012190 | CISPLATIN + DOXORUBICIN |
| 330003106 | 330006873 | null | 75.8 | Palliative (P) | 2015-04-30 | 2015-07-03 | Cisplatin + Doxorubicin | 02 | N | 330012194 | CISPLATIN + DOXORUBICIN |
| 330003107 | 330001643 | 0 | 67.1 | Palliative (P) | null | 2017-01-21 | Rituximab | null | null | 330012198 | RITUXIMAB |
| 330003108 | 330001644 | 0 | 91 | Adjuvant (A) | 2013-03-18 | 2013-04-10 | Cisplatin + Doxorubicin | 2 | Y | 330012199 | CISPLATIN + DOXORUBICIN |
| 330003109 | 330001644 | 1.65 | 58 | Curative (C) | 2017-03-29 | 2017-04-05 | Liposomal Doxorubicin (20mg/m2) | 2 | N | 330012199 | LIPOSOMAL DOXORUBICIN |
| 330003110 | 330001645 | 1.64 | 100 | null | 2015-05-23 | 2015-05-24 | Bendamustine+Rituximab(Sub Courses) | 2 | null | 330012201 | BENDAMUSTINE + RITUXIMAB |
| 330003111 | 330006875 | 1.87 | 24.3 | Palliative (P) | 2015-09-13 | 2015-09-14 | DOXORUBICIN | N | N | 330012203 | DOXORUBICIN |
| 330003112 | 330006875 | 1.55 | 90.2 | null | 2014-08-13 | 2014-08-13 | Rituximab | N | N | 330012203 | RITUXIMAB |
| 330003113 | 330006875 | 1.6 | 56 | Palliative (P) | null | 2018-02-16 | Liposomal Doxorubicin (20mg/m2) | N | N | 330012203 | LIPOSOMAL DOXORUBICIN |
| 330003114 | 330001646 | 1.6 | 52 | Palliative (P) | 2013-06-05 | 2013-06-09 | Cisplatin + Doxorubicin | 2 | N | 330012214 | CISPLATIN + DOXORUBICIN |
| 330003115 | 330001646 | null | 52 | Neo-adjuvant (N) | 2017-11-01 | 2018-01-10 | Carboplatin + Paclitaxel (3 weekly) | N | N | 330012214 | CARBOPLATIN + PACLITAXEL |
| 330003116 | 330001647 | 1.63 | 92.7 | null | 2017-10-24 | 2017-11-04 | Liposomal Doxorubicin (Caelyx) | 2 | Y | 330012218 | LIPOSOMAL DOXORUBICIN |
| 330003118 | 330006877 | 1.61 | 75.1 | Palliative (P) | 2015-11-09 | 2015-11-16 | DOXORUBICIN | 2 | N | 330012220 | DOXORUBICIN |
| 330003119 | 330009710 | 1.78 | 78 | Palliative (P) | 2014-01-07 | 2014-01-09 | BENDAMUSTINE + RITUXIMAB | 02 | N | 330012224 | BENDAMUSTINE + RITUXIMAB |
| 330003120 | 330009710 | 1.84 | 87.2 | Not known (9) | 2014-06-30 | 2014-07-12 | CARBOPLATIN + PACLITAXEL | null | null | 330012224 | CARBOPLATIN + PACLITAXEL |
| 330003121 | 330001649 | 1.42 | 7.5 | Palliative (P) | null | 2017-06-22 | Doxorubicin 75mg/m2 | null | null | 330012228 | DOXORUBICIN |
| 330003122 | 330001650 | 1.7 | 96 | Palliative (P) | 2015-03-30 | 2015-04-01 | Doxorubicin 75mg/m2 | null | N | 330012230 | DOXORUBICIN |
| 330003123 | 330001651 | 1.55 | 89 | null | null | 2014-01-20 | Cisplatin + Doxorubicin | 1 | null | 330012231 | CISPLATIN + DOXORUBICIN |
| 330003124 | 330001652 | 1.76 | 11.7 | Disease modification (D) | 2018-06-21 | 2018-06-21 | Rituximab | 2 | Y | 330012232 | RITUXIMAB |
| 330003125 | 330001652 | 1.82 | 77.7 | Neo-adjuvant (N) | 2014-03-09 | 2014-03-16 | Cisplatin + Doxorubicin | null | null | 330012232 | CISPLATIN + DOXORUBICIN |
| 330003126 | 330001652 | 1.56 | 79.5 | null | 2015-08-14 | 2015-08-23 | Doxorubicin 75mg/m2 | N | N | 330012232 | DOXORUBICIN |
| 330003127 | 330001653 | 1.8 | 75 | Palliative (P) | 2013-10-05 | 2013-10-05 | Carboplatin + Etoposide iv&po | 2 | N | 330012236 | CARBOPLATIN + ETOPOSIDE |
| 330003128 | 330001654 | 1.83 | 113 | Curative (C) | 2016-03-26 | 2016-04-01 | Rituximab | N | N | 330012237 | RITUXIMAB |
| 330003129 | 330006879 | 0 | 52 | Disease modification (D) | 2013-09-12 | 2013-09-12 | Rituximab | N | N | 330012238 | RITUXIMAB |
| 330003131 | 330006880 | 1.65 | 53.4 | null | 2014-04-28 | 2014-04-29 | Rituximab | N | N | 330012246 | RITUXIMAB |
| 330003132 | 330006880 | 1.69 | null | Adjuvant (A) | 2017-07-09 | 2017-07-09 | CARBOPLATIN + PACLITAXEL | 2 | N | 330012246 | CARBOPLATIN + PACLITAXEL |
| 330003133 | 330011285 | 1.78 | 66 | Palliative (P) | 2018-01-22 | 2018-01-22 | DOXORUBICIN | 02 | N | 330012248 | DOXORUBICIN |
| 330003134 | 330011285 | 1.51 | 46.4 | null | 2017-06-20 | 2017-07-02 | Rituximab | N | N | 330012248 | RITUXIMAB |
| 330003135 | 330011285 | 1.77 | 74 | null | 2015-08-16 | 2015-08-16 | Rituximab | N | N | 330012248 | RITUXIMAB |
| 330003136 | 330011285 | 1.72 | 75.4 | Palliative (P) | 2015-02-20 | 2015-02-21 | Liposomal Doxorubicin (Caelyx) | 02 | N | 330012248 | LIPOSOMAL DOXORUBICIN |
| 330003137 | 330011285 | 1.9 | 82 | Palliative (P) | 2016-03-10 | 2016-03-15 | DOXORUBICIN | 02 | N | 330012248 | DOXORUBICIN |
| 330003138 | 330001656 | null | 81 | null | 2014-01-28 | 2014-01-28 | Cisplatin + Doxorubicin | 2 | N | 330012257 | CISPLATIN + DOXORUBICIN |
| 330003139 | 330006881 | 1.6 | 75 | Palliative (P) | 2015-05-30 | 2015-05-30 | Carboplatin + Etoposide IV 3 day | N | N | 330012258 | CARBOPLATIN + ETOPOSIDE |